Sector News

Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m

January 23, 2021
Life sciences

Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash.

Founded 20 years ago, Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.

Thermo Fisher executive vice-president Michel Lagarde said: “The addition of their manufacturing capabilities in Europe complements our four development and manufacturing sites in North America.

“In addition, they bring an incredibly talented team with more than two decades of experience across a broad range of viral vectors.

“The combination will benefit our global customers seeking support and capacity in the region as well as European customers bringing new medicines to patients inside and outside of Europe.”

The viral vector manufacturing business offers over 7,000m² of advanced clinical and commercial manufacturing capacity.

With two locations in Seneffe and Gosselies, Henogen has around 400 employees with extensive operational and technical proficiency in various viral vector classes.

Novasep president and CEO Michel Spagnol said: “Our diverse customer base will benefit from the combination of our viral vector services capabilities with the scale and capabilities of Thermo Fisher.

“Our talented employees will bring deep expertise to an organisation that shares our commitment to providing ground-breaking new medicines to patients.”

The business will be part of the Pharma Services business within the Laboratory Products and Services Segment.

In March 2019, Thermo Fisher Scientific signed a definitive agreement to acquire viral vector manufacturing company Brammer Bio for a cash consideration of around $1.7bn.

Brammer Bio is focused on the clinical and commercial supply of vectors for in vivo gene therapy and ex vivo gene-modified cell therapy.

by Pharmaceutical-Technology.com

Source: pharmaceutical-technology.com

Related News

May 1, 2021

AbbVie remains one of the best buys in its sector

Life sciences

AbbVie will be among the stocks closing out a busy earnings week. Earnings season tends to draw a lot of interest from investors, but it’s not always the best indicator of a stock’s overall trajectory.

May 1, 2021

Pfizer buys infectious disease biotech Amplyx

Life sciences

Pfizer has bought privately held Amplyx Pharmaceuticals for an undisclosed sum, gaining experimental antifungal and antiviral treatments as the world’s attention turns more toward infectious diseases.

May 1, 2021

Medtronic taps virtual reality ‘flight simulators’ for brain surgery, built from 3D patient scans

Life sciences

Surgical Theater’s technology builds 3D models of an individual patient’s anatomy from CT and MRI scans to offer surgeons an immersive, 360-degree fly-through view.

Send this to a friend